|
|
|
|
|
by nradov
907 days ago
|
|
Gold's Gym and CrossFit already exist to target consumers who want a more toned, muscular appearance. They have been around for a while and should be sustainable as long as they don't do something stupid like take on huge debts to fuel rapid expansion. Any new market entrants will have to come up with a unique angle to compete against those established players. Tonal also appears to be getting some traction in the home strength training market but it's not clear whether they can survive. GLP-1 drugs like Ozempic can be very effective for rapid weight loss but I think (hope?) that consumers will eventually become disillusioned with them. There are significant side effects in many patients, the weight tends to come back when the drug is stopped, and much of the weight lost is lean muscle rather than adipose tissue. There is a growing body of evidence that having a large amount of skeletal muscle is crucial for maintaining metabolic health (glucose sink) and preventing disabling falls later in life (sarcopenia). |
|
1) I'm having trouble finding a good citation, but I remember it being a minor scandal at some point that statistically, the real-world weight loss from semaglutide was found to be roughly half what it was in the trials, probably because the trial populations were unrepresentative (younger and fewer comorbidities than the real-world population, IIRC).
2) In the face of shortages of the standard branded Ozempic/Wegovy products, a lot of people are turning to compounding pharmacies. But according to Novo Nordisk, there is no legitimate supply chain of semaglutide for them to use, so these pharmacies are apparently selling people a semaglutide salt that is manufactured as a research chemical rather than a licensed drug [1]. The FDA has also warned of outright counterfeit Ozempic getting into the supply chain, complete with fake serial and lot numbers [2].
[1] https://www.nbcnews.com/health/health-news/ozempic-wegovy-we...
[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-w...